# Irritable Bowel Syndrome: Positive Diagnosis and Multimodal Treatment

## Introduction

Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction affecting approximately 10 to 15% of the global population. It is one of the most common conditions encountered in primary care and gastroenterology. A positive diagnostic approach based on symptom criteria, rather than exhaustive exclusionary testing, reduces healthcare costs and patient anxiety.

## Diagnosis

### Rome IV Criteria

The Rome IV criteria define IBS as recurrent abdominal pain on average at least 1 day per week in the last 3 months, associated with two or more of the following: the pain is related to defecation (improvement or worsening), associated with a change in stool frequency, or associated with a change in stool form (appearance). Symptom onset must be at least 6 months before diagnosis, and criteria must be fulfilled for the last 3 months.

### IBS Subtypes

IBS-C (constipation predominant) involves hard or lumpy stools in 25% or more of bowel movements. IBS-D (diarrhea predominant) involves loose or watery stools in 25% or more of bowel movements. IBS-M (mixed) involves both hard and loose stools each in 25% or more. IBS-U (unsubtyped) does not meet criteria for the other subtypes. The Bristol Stool Form Scale is used to classify stool consistency.

### Positive Diagnosis Approach

IBS is a clinical diagnosis based on symptom criteria, and extensive testing is not required in the absence of alarm features. Making a confident, positive diagnosis reduces patient anxiety and unnecessary procedures. Alarm features that warrant further investigation include rectal bleeding, unintentional weight loss, nocturnal symptoms, family history of colorectal cancer, inflammatory bowel disease or celiac disease, and onset after age 50.

### Limited Workup

A CBC rules out anemia. CRP and fecal calprotectin, when normal, help exclude inflammatory bowel disease. Celiac serologies (tissue transglutaminase IgA) are important because celiac disease prevalence is 4 times higher in patients with IBS-like symptoms. Thyroid function testing is appropriate if symptoms suggest thyroid dysfunction. Colonoscopy is not routinely required unless alarm features are present or the patient is due for colorectal cancer screening.

![Diagnostic flowchart for IBS using Rome IV criteria with limited laboratory workup](images/ibs-diagnostic-flowchart.jpg)

## Pathophysiology

The pathophysiology of IBS involves multiple interacting mechanisms. Altered gut motility produces increased or decreased transit time depending on the subtype. Visceral hypersensitivity results in heightened perception of normal gut distention and motility. Gut-brain axis dysregulation involves bidirectional communication between the central nervous system and enteric nervous system. Increased intestinal permeability and low-grade mucosal inflammation play a role. Gut microbiome alterations and dysbiosis may contribute to symptom generation. Post-infectious IBS develops in approximately 10 to 15% of patients after acute gastroenteritis. Psychological comorbidity, with anxiety and depression present in 40 to 60% of IBS patients, is a significant factor.

## Multimodal Treatment

### Patient Education and Therapeutic Relationship

Validating the diagnosis is essential: IBS is a real, physiologic condition, not "all in the head." The gut-brain axis concept should be explained in accessible terms. Realistic expectations should be set, as the goal is symptom management rather than cure. A consistent therapeutic relationship should be established, and dismissive language avoided.

### Dietary Interventions

The low-FODMAP diet restricts fermentable oligosaccharides, disaccharides, monosaccharides, and polyols and is effective in approximately 50 to 70% of patients. It involves three phases: elimination (2 to 6 weeks), reintroduction, and personalization. Referral to a dietitian trained in FODMAP implementation improves outcomes. Soluble fiber supplementation with psyllium is beneficial for IBS-C, while insoluble fiber such as bran may worsen bloating. Individual trigger foods should be identified and limited, with common triggers including caffeine, alcohol, fatty foods, and artificial sweeteners. Regular meal timing and avoiding skipped meals support symptom management.

### Pharmacotherapy

| Subtype | Agent | Mechanism | Key Notes |
|---------|-------|-----------|-----------|
| IBS-C | Linaclotide (Linzess) | Guanylate cyclase-C agonist | Improves pain + constipation |
| IBS-C | Lubiprostone (Amitiza) | Chloride channel activator | — |
| IBS-C | PEG 3350 (MiraLAX) | Osmotic laxative | Limited pain benefit |
| IBS-D | Loperamide | Slows transit | No pain benefit |
| IBS-D | Rifaximin (Xifaxan) | Non-absorbed antibiotic (2-wk course) | Can repeat for recurrence |
| IBS-D | Eluxadoline (Viberzi) | Mixed opioid receptor agonist/antagonist | Contraindicated without gallbladder |
| All (pain) | TCA (amitriptyline 10-50 mg) | Neuromodulator | First-line for visceral pain |
| All (pain) | Peppermint oil (enteric-coated) | Smooth muscle relaxant | Evidence supports for pain/bloating |

#### IBS-C

Linaclotide (Linzess) is a guanylate cyclase-C agonist that improves both constipation and abdominal pain. Lubiprostone (Amitiza) is a chloride channel activator. PEG 3350 (MiraLAX) is an osmotic laxative that improves stool frequency but has limited effect on pain. Plecanatide (Trulance) is another guanylate cyclase-C agonist similar to linaclotide. Tegaserod is a 5-HT4 agonist available for women under 65 without cardiovascular risk factors.

#### IBS-D

Loperamide slows transit and improves diarrhea but does not reduce pain. Rifaximin (Xifaxan) is a non-absorbed antibiotic given as a 2-week course that can be repeated for symptom recurrence. Eluxadoline (Viberzi) is a mixed opioid receptor agonist/antagonist that is contraindicated in patients without a gallbladder. Alosetron (Lotronex) is a 5-HT3 antagonist for severe IBS-D in women, with restricted prescribing due to the risk of ischemic colitis. Bile acid sequestrants such as cholestyramine are effective when bile acid malabsorption contributes.

#### For All Subtypes (Pain-Predominant)

Antispasmodics such as dicyclomine and hyoscyamine are taken before meals; they have limited evidence but are widely used. Enteric-coated peppermint oil reduces smooth muscle spasm, and evidence supports its efficacy for pain and bloating. Tricyclic antidepressants (amitriptyline or nortriptyline at 10 to 50 mg) serve as first-line neuromodulators for pain and should be started low and titrated. SSRIs such as citalopram and fluoxetine are beneficial when anxiety or depression coexist but have less effect on visceral pain than TCAs.

![Table comparing pharmacologic options for IBS-C, IBS-D, and pain-predominant IBS](images/ibs-pharmacotherapy-table.jpg)

### Psychological Therapies

Cognitive behavioral therapy (CBT) has the strongest evidence among psychological treatments and addresses catastrophizing and avoidance behaviors. Gut-directed hypnotherapy is effective for refractory IBS and reduces visceral hypersensitivity. Mindfulness-based stress reduction (MBSR) is another option. These therapies are recommended by the AGA, particularly for patients not responding to first-line treatments. Psychological comorbidities including anxiety, depression, and trauma history should be addressed as part of comprehensive management.

![Pyramid illustrating the multimodal treatment approach for IBS from lifestyle modifications through pharmacotherapy and psychological interventions](images/ibs-treatment-pyramid.jpg)

## Key Clinical Pearls

A positive diagnosis of IBS should be made using Rome IV criteria, and excessive testing that reinforces patient anxiety and delays treatment should be avoided. The low-FODMAP diet is the most effective dietary intervention but should be implemented with dietitian guidance to prevent unnecessary long-term restriction. Neuromodulators, specifically TCAs at low doses, are the most effective pharmacologic option for visceral pain across IBS subtypes. Psychological therapies, particularly CBT and gut-directed hypnotherapy, have durable efficacy and should be offered early rather than as a last resort.

## References

1. Lacy BE, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. *Am J Gastroenterol*. 2021;116(1):17-44.
2. Ford AC, et al. Irritable bowel syndrome. *Lancet*. 2020;396(10263):1675-1688.
3. Black CJ, et al. Efficacy of psychological therapies for IBS: systematic review and network meta-analysis. *Gut*. 2020;69(8):1441-1451.
4. Moayyedi P, et al. The effect of fiber supplementation on IBS: a systematic review and meta-analysis. *Am J Gastroenterol*. 2014;109(9):1367-1374.